Weekly Paclitaxel given concurrently with Durvalumab has a favorable safety profile in triple-negative metastatic breast cancer

Therapeutic anti-PD-L1 antibodies are safe as a monotherapy, albeit with minimal efficacy in triple-negative breast cancer (TNBC). This trial aimed to test the safety and efficacy of Durvalumab and Paclitaxel in metastatic TNBC. In this open-label, one-arm trial, five cycles of weekly paclitaxel wer...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghebeh, Hazem, Al-Sayed, Adher, Eiada, Riham, Cabangon, Leilani, Ajarim, Dahish, Suleman, Kausar, Tulbah, Asma, Al-Tweigeri, Taher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8476586/
https://www.ncbi.nlm.nih.gov/pubmed/34580336
http://dx.doi.org/10.1038/s41598-021-98113-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8476586/
https://www.ncbi.nlm.nih.gov/pubmed/34580336
http://dx.doi.org/10.1038/s41598-021-98113-6

Ejemplares similares